Back to Authors

Hamdi, Osama

0000-0002-3495-9231

Mayo Clinic

Howard University College of Medicine, Washington, District of Columbia, U.S.A.

Citations 2

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement
Sidell, Douglas R. , Balakrishnan, Karthik , Best, Simon R. , Zur, Karen B. , Buckingham, Julia C., Alarcón, Alessandro de , Baroody, Fuad M. , Bock, Jonathan M. , Boss, Emily F. , Bower, Charles M. , Clarke, Jeffrey , Clarke, Kevin D., Cocciaglia, Alejandro , Cotton, Robin T., Cuestas, Giselle , Davis, Kara L. , Defagó, Victor, Dikkers, Frederik G. , Dossans, Ines, Guerra, Walter Florez , Fox, Elizabeth , Friedman, Aaron D. , Grant, Nazaneen N. , Hogikyan, Norman D. , Johnson, Kaalan , Johnson, Liane B. , Johnson, Romaine F. , Kelly, Peggy, Klein, Adam M. , Lawlor, Claire M. , Levy, Alejandro G., Licameli, Greg R. , Long, Steve, Manrique, Dayse , McMurray, J. Scott , Meister, Kara D. , Messner, Anna H. , Möhr, Michael , Mortelliti, Anthony J., Novakovic, Daniel , Ongkasuwan, Julina , Piersiala, Krzysztof , Prager, Jeremy D. , Pransky, Seth M. , Raynor, Tiffany , Rodríguez, Hugo, Rodríguez, Verónica P., Scatolini, María Laura , Scheffler, Patrick , Smith, David F. , Smith, Lee P., Smith, Marshall E. , Smith, Richard J. , Sorom, Abraham, Steinberg, Amalia, Stith, John A., Thompson, Dana M. , Thompson, Jerome W. , Varela, Patricio, White, David R. , Wineland, Andre , Yang, Christina J. , Zdanski, Carlton J. , Derkay, Craig S. , Zur, Karen , de Alarcón, Alessandro , Campisi, Paolo , Friedman, Aaron D , Hamdi, Osama , Johnson, Romaine F , Leboulanger, Nicolas , Meister, Kara D , Novakovic, Daniel , Ongkasuwan, Julian , Prager, Jeremy D , Rinkel, Rico N P M , Smith, David F , Wineland, Andre M , Sidell, Douglas R , Davis, Kara L , Balakrishnan, Karthik , Buckingham, Julia, Chen, Sharon , Hamdi, Osama A. , Leboulanger, Nicolas , Lam, Derek J. , Long, Steve, Lott, David G. , Mudd, Pamela A. , Peer, Shazia , Preciado, Diego A. , Russell, John

The Laryngoscope | January 8, 2021 | Volume: 131 | Issue: 6 | Pages: No page available

10.1002/lary.29343 Get It

Objectives/HypothesisThe purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.Study DesignDelphi method‐based survey series.MethodsA multidisciplinary, multi‐institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work‐up.ResultsThe international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).ConclusionThis consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best‐practice applications of systemic bevacizumab for patients with early‐onset or less‐severe disease phenotypes.Level of Evidence5 Laryngoscope, 131:E1941–E1949, 2021
The Relationship between Croup and Gastroesophageal Reflux: A Systematic Review and Meta‐Analysis
Coughran, Alanna, Balakrishnan, Karthik , Vaezeafshar, Reza, Capdarest‐Arest, Nicole , Hamdi, Osama A. , Sidell, Douglas R. , Sidell, Douglas R. , Capdarest-Arest, Nicole , Hamdi, Osama , Sidell, Douglas R , Sidell, Douglas R , Balakrishnan, Karthik , Ma, Yifei

The Laryngoscope | February 10, 2020 | Volume: 131 | Issue: 1 | Pages: 209-217

10.1002/lary.28544 Get It

ObjectiveThe mechanism by which recurrent croup occurs is unknown. Gastroesophageal reflux is commonly implicated, although this relationship is only loosely documented. We conducted a systematic review with a meta‐analysis component to evaluate the relationship between recurrent croup and gastroesophageal reflux disease (GERD), and to assess for evidence of improvement in croup symptoms when treated.Style DesignSystematic Review and Meta Analysis.MethodsWe searched five separate databases. Studies were included if they discussed the relationship between croup and GERD in children, >5 subjects, and available in English. Literature retrieved was assessed according to pre‐specified criteria. Retrieved articles were reviewed by two independent authors and decisions mediated by a third author. If there was a difference of opinion after first review, a second review was performed to obtain consensus. Heterogeneity was calculated and summarized in forest plots.ResultsOf 346 initial records, 15 met inclusion criteria. These were two retrospective cohort and 13 cross‐sectional studies. Thirteen of 15 articles support an association between recurrent croup and GERD. Although heterogeneity is high among studies that reported prevalence of GERD, there is less uncertainty in results for improvement to recurrent croup after GERD treatment. Most studies lacked a control group and all carry a moderate‐to‐high risk of bias.ConclusionThere is limited evidence linking GERD to recurrent croup; Further research is needed to assess for causality as most studies are retrospective, lack a control group, and have a study design exposing them to bias. Patients treated with reflux medication appear to demonstrate a reduced incidence of croup symptoms.Level of Evidence1 Laryngoscope, 131:209–217, 2021